Recent Company News

• 05:36 AM ET Mar 31, 2026
  

  Guo Guangchang: Fosun International's NAV reaches HKD18.1 Per Share, Focusing Resources on Core, High--Growth Areas

• 05:22 AM ET Mar 31, 2026
  

  NMPA approves Shanghai Henlius Biotech HLXTE-HAase02 to phase I clinical trial for improving results of subcutaneous delivery (HK$19.82, 0.00)

• 05:18 AM ET Mar 31, 2026
  

  NMPA approves Shanghai Fosun Pharma FXB0871 to phase I clinical trial for treatment of advanced solid tumors (HK$19.82, 0.00)

• 11:26 AM ET Mar 30, 2026
  

  Fosun International: Total Revenue in 2025 Reaches RMB173.43 Billion, with Overseas Revenue Accounting for 54.7%, Aiming to Achieve"RMB10 Billion in Profit"

• 11:14 AM ET Mar 30, 2026
  

  Guo Guangchang's Letter to Shareholders: "Repair the Roof While the Sun Is Shining" -- Fosun Aims to Go Further with Greater Stability

• 10:16 AM ET Mar 30, 2026
  

  Fosun International to increase dividend payout ratio from 20% to 35% from FY26 (HK$4.04, 0.00)

• 10:14 AM ET Mar 30, 2026
  

  Fosun International reports FY net income attributable (CNY23.40B) vs guidance (CNY21.5-23.5B) and FactSet (CNY15.30B) [3 est, (CNY22.65)-(777.6M)] (HK$4.04, 0.00)